首页 | 本学科首页   官方微博 | 高级检索  
检索        

拉米夫定联合阿德福韦酯治疗乙型肝炎相关性肝癌的生存分析
引用本文:李勤英,胡晓锋,赵玲俊,曹新桥,李志伟,李蕴铷.拉米夫定联合阿德福韦酯治疗乙型肝炎相关性肝癌的生存分析[J].河北医学,2014(3):491-493.
作者姓名:李勤英  胡晓锋  赵玲俊  曹新桥  李志伟  李蕴铷
作者单位:[1] 河北省衡水市第三人民医院,河北衡水053000 [2] 河北省衡水卫生学 校,河北衡水053000 [3] 河北省衡水市哈励逊国际和平医院,河北衡水053000 [4] 首都医科大学附属北京地坛医院,北京100015
摘    要:目的:探讨拉米夫定联合阿德福韦酯联合治疗对乙型肝炎相关性肝癌生存的影响。方法:回顾性分析2008年7月至2011年1月以来我院门诊及住院的55例HBV-DNA阳性的原发性肝癌患者,治疗组30例,对照组25例,两组均给予相同的针对肿瘤的治疗,治疗组应用拉米夫定联合阿德福韦酯抗病毒治疗,对照组不给于抗病毒治疗。采用log rank检验两组生存时间差异,用Kaplan-Meier绘制患者生存曲线。结果:治疗组患者生存时间高于对照组,两组差异有显著性( P<0.05)。结论:拉米夫定联合阿德福韦酯治疗乙肝相关性肝癌术后患者可以延长患者的生存期。

关 键 词:拉米夫定  阿德福韦酯      生存分析

Survival Analysis of Patients of Hepatic Carcinoma Related to Hepatitis B after Combination Therapy of Lamivudine with Adefovir Dipivoxil
Abstract:Objective: To analyze the clinical factors predicting long-term survival after combination therapy of lamivudine with adefovir dipivoxil in hepatic carcinoma related to hepatitis B .Method:The clini-cal data of 55 patients with hepatic carcinoma who underwent combination therapy of lamivudine with adefovir dipivoxil from 2009 to 2012 were analyzed Retrospectively .The patients were divided into antiviral group ( 30 cases treated with lamivudine with adefovir dipivoxil ) and non-antiviral group ( 25 cases without antivirus therapy ) .Both of two group were treated with resection of liver cancer or transcatheter arterial chemoemboli-zation.Result:The survival time of antiviral group was longer than non-antiviral group(P<0.05).Conclu-sion:Combination therapy of lamivudine with adefovir dipivoxil in hepatic carcinoma related to hepatitis B can improve suvival time .
Keywords:Lamivudin  Adefovir dipivoxil  Hepatic carcinoma  Survival analysis
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号